| Status | Study |
| Not yet recruiting |
Study Name: Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Condition: Castration-Resistant Prostatic Cancer Metastatic Prostate Carcinoma Date: 2016-12-01 Interventions: Biological: GnRH agonist/antagonist |
| Recruiting |
Study Name: Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Condition: Androgen Receptor Positive Estrogen Receptor Negative Date: 2016-11-21 Interventions: Drug: Enobosarm Given PO |
| Recruiting |
Study Name: Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers Condition: Salivary Cancer Date: 2016-04-21 Interventions: Drug: enzalutamide oral |
| Recruiting |
Study Name: Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC) Condition: Breast Cancer Date: 2016-02-12 Interventions: Drug: Enzalutamide 120 mg by m |
| Active, not recruiting |
Study Name: MRI in Patients With Kennedy Disease Condition: Bulbo-Spinal Atrophy, X-Linked Kennedy Disease Date: 2015-07-14 Interventions: Other: No intervention, observational |
| Recruiting |
Study Name: A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer Condition: Prostate Cancer Date: 2015-07-06 Interventions: Drug: LY2452473 LY2452473 is a |
| Suspended |
Study Name: Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Condition: Estrogen Receptor Negative Estrogen Receptor Positive HER2 Date: 2015-05-21 Interventions: Other: Biomarker Analysis Corr |
| Recruiting |
Study Name: A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF Condition: Prostate Cancer Date: 2015-03-27 Interventions: Biological: pTVG-AR Given ID |
| Recruiting |
Study Name: Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) Condition: Triple Negative Breast Cancer Date: 2015-02-10 Interventions: Drug: GTx-024 GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg |
| Active, not recruiting |
Study Name: High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy Condition: Spinal and Bulbar Muscular Atrophy Healthy Subjects Date: 2014-06-04 Interventions: Other: Supervised high intensity training |